Related Experiment Video
Updated: Oct 5, 2025
Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
COVID-19 and Panax ginseng: Targeting platelet aggregation, thrombosis and the coagulation pathway
Yuan Yee Lee1,2,3, Yixian Quah4, Jung-Hae Shin1,2,3
1Ginseng Circulatonic Laboratory, College of Veterinary Medicine, Kyungpook National University, Daegu, Republic of Korea.
Insights
Panax ginseng may help prevent COVID-19 complications, particularly thrombosis. This review explores its potential benefits against blood clots and immune responses associated with the virus.
Area of Science:
- Pharmacology
- Immunology
- Natural Products Research
Background:
- Coronavirus disease 2019 (COVID-19) presents multifaceted health risks beyond respiratory issues, including cytokine storms and thrombotic events.
- Thrombotic complications significantly impact COVID-19 patient mortality and morbidity.
- Natural products, like Panax ginseng, are explored for their potential health benefits and immune-modulating properties.
Purpose of the Study:
- To investigate the potential of Panax ginseng as a supplement to mitigate COVID-19-associated complications, with a focus on thrombosis.
- To validate the therapeutic properties of Panax ginseng against COVID-19-mediated thrombosis using network pharmacology.
- To explore the role of Panax ginseng in addressing platelet-leukocyte aggregates and immunity-related responses in COVID-19.
Main Methods:
- Literature review and network pharmacology approach.
- Analysis of Panax ginseng's known therapeutic effects on cardiovascular disease, thrombosis, and platelet aggregation.
- Investigation into the mechanisms underlying Panax ginseng's potential impact on coagulation pathways and immune responses.
Main Results:
- Panax ginseng exhibits therapeutic potential against cardiovascular disease, thrombosis, and platelet aggregation.
- Network pharmacology validates the proposed benefits of Panax ginseng in combating COVID-19-related thrombosis.
- Potential mechanisms involving platelet-leukocyte aggregates and immune responses are being investigated.
Conclusions:
- Panax ginseng shows promise as a natural supplement to manage COVID-19 complications, especially thrombosis.
- Further research into its effects on coagulation and immune pathways is warranted.
- Panax ginseng could offer a complementary approach to managing severe COVID-19 outcomes.
Abstract:
Coronavirus disease 2019 (COVID-19) not only targets the respiratory system but also triggers a cytokine storm and a series of complications, such as gastrointestinal problems, acute kidney injury, and myocardial ischemia. The use of natural products has been utilized to ease the symptoms of COVID-19, and in some cases, to strengthen the immune system against COVID-19. Natural products are readily available and have been regularly consumed for various health benefits. COVID-19 has been reported to be associated with the risk of thromboembolism and deep vein thrombosis. These thrombotic complications often affects mortality and morbidity. Panax ginseng, which has been widely consumed for its various health benefits has also been reported for its therapeutic effects against cardiovascular disease, thrombosis and platelet aggregation. In this review, we propose that P. ginseng can be consumed as a supplementation against the various associated complications of COVID-19, especially against thrombosis. We utilized the network pharmacology approach to validate the potential therapeutic properties of P. ginseng against COVID-19 mediated thrombosis, the coagulation pathway and platelet aggregation. Additionally, we aimed to investigate the roles of P. ginseng against COVID-19 with the involvement of platelet-leukocyte aggregates in relation to immunity-related responses in COVID-19.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:22Formation of the Platelet Plug
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...